All In Biotech

NDA 219285 · Genentech INC

Evrysdi

Risdiplam · Oral · Survival of Motor Neuron 2 Splicing Modifier

Orphan

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Feb 11, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

22

4 Phase 3, 5 recruiting

FAERS reports

4,186

1,909 serious, 437 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 2, 2026.

EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. ( 1 )

Mechanism: Risdiplam is a survival of motor neuron 2 (SMN2) splicing modifier designed to treat patients with spinal muscular atrophy (SMA) caused by mutations in chromosome 5q that lead to SMN protein deficiency. Using in vitro assays and studies in transgenic animal models of SMA, risdiplam was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein in the brain. In vitro and in vivo data indicate that risdiplam may cause alternative splicing of additional genes, including FOXM1 and MADD. FOXM1 and MADD are thought to be...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • EVRYSDI · RISDIPLAM 5MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Risdiplam" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event356
  • diarrhoea300
  • asthenia230
  • pneumonia225
  • death215
  • pyrexia186
  • fatigue162
  • vomiting149
  • muscular weakness146
  • drug ineffective140
  • rash114
  • headache111

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20193
2020137
2021594
2022559
2023698
20241,378
2025483
2026334

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Evrysdi (Risdiplam)

2024 spending

$155M

Beneficiaries

471

5,578 claims

Per beneficiary

$328,087

$165.95 per unit

View as table
YearSpending
2020$15,161,292
2021$91,959,282
2022$120,799,423
2023$132,416,369
2024$154,528,772

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 32 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.